The Current Status of DNA-Repair-Directed Precision Oncology Strategies in Epithelial Ovarian Cancers.
Hiu TangSanat KulkarniChristina PetersJasper EddisonMaryam Al-AniSrinivasan MadhusudanPublished in: International journal of molecular sciences (2023)
Survival outcomes for patients with advanced ovarian cancer remain poor despite advances in chemotherapy and surgery. Platinum-based systemic chemotherapy can result in a response rate of up to 80%, but most patients will have recurrence and die from the disease. Recently, the DNA-repair-directed precision oncology strategy has generated hope for patients. The clinical use of poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA germ-line-deficient and/or platinum-sensitive epithelial ovarian cancers has improved survival. However, the emergence of resistance is an ongoing clinical challenge. Here, we review the current clinical state of PARP inhibitors and other clinically viable targeted approaches in epithelial ovarian cancers.
Keyphrases
- dna repair
- dna damage
- end stage renal disease
- newly diagnosed
- ejection fraction
- palliative care
- minimally invasive
- dna damage response
- prognostic factors
- peritoneal dialysis
- cancer therapy
- patient reported outcomes
- acute coronary syndrome
- radiation therapy
- locally advanced
- young adults
- rectal cancer
- atrial fibrillation
- percutaneous coronary intervention
- free survival